These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25963079)

  • 1. Potential Serum Markers for Monitoring the Progression of Hepatitis B Virus-Associated Chronic Hepatic Lesions to Liver Cirrhosis.
    Wu C; Liu L; Zhao P; Tang D; Yao D; Zhu L; Wang Z
    Gut Liver; 2015 Sep; 9(5):665-71. PubMed ID: 25963079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.
    Wu C; Wang Z; Liu L; Zhao P; Wang W; Yao D; Shi B; Lu J; Liao P; Yang Y; Zhu L
    J Gastroenterol Hepatol; 2009 Jan; 24(1):55-62. PubMed ID: 18823443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification.
    Cui J; Kang X; Dai Z; Huang C; Zhou H; Guo K; Li Y; Zhang Y; Sun R; Chen J; Li Y; Tang Z; Uemura T; Liu Y
    J Cancer Res Clin Oncol; 2007 Nov; 133(11):825-34. PubMed ID: 17516088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SELDI-TOF MS proteinchip technology for screening of serum markers of HBV-induced hepatocellular carcinoma.
    Geng X; Wang F; Li YG; Zhu GP; Zhang WM
    J Exp Clin Cancer Res; 2007 Dec; 26(4):505-8. PubMed ID: 18365545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples.
    Göbel T; Vorderwülbecke S; Hauck K; Fey H; Häussinger D; Erhardt A
    World J Gastroenterol; 2006 Dec; 12(47):7604-12. PubMed ID: 17171788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum peptide profiles during progression of chronic hepatitis B virus infection to liver failure.
    Han T; Liu H; Yu ZL; Li J; Wang L; Xiao SX; Li Y; Yu ML
    J Viral Hepat; 2010 Mar; 17 Suppl 1():18-23. PubMed ID: 20586930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.
    Zinkin NT; Grall F; Bhaskar K; Otu HH; Spentzos D; Kalmowitz B; Wells M; Guerrero M; Asara JM; Libermann TA; Afdhal NH
    Clin Cancer Res; 2008 Jan; 14(2):470-7. PubMed ID: 18223221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma lipidomic fingerprinting to distinguish among hepatitis C-related hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis C using MALDI-TOF mass spectrometry: a pilot study.
    Passos-Castilho AM; Lo Turco E; Ferraz ML; Matos C; Silva I; Parise E; Pilau E; Gozzo F; Granato C
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):43-9. PubMed ID: 25822433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of serum protein fingerprinting coupled with artificial neural network model in diagnosis of hepatocellular carcinoma.
    Wang JX; Zhang B; Yu JK; Liu J; Yang MQ; Zheng S
    Chin Med J (Engl); 2005 Aug; 118(15):1278-84. PubMed ID: 16117882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toward the proteomic identification of biomarkers for the prediction of HBV related hepatocellular carcinoma.
    He QY; Zhu R; Lei T; Ng MY; Luk JM; Sham P; Lau GK; Chiu JF
    J Cell Biochem; 2008 Feb; 103(3):740-52. PubMed ID: 17557278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum profiling based on fucosylated glycoproteins for differentiating between chronic hepatitis B and hepatocellular carcinoma.
    Liao J; Zhang R; Qian H; Cao L; Zhang Y; Xu W; Li J; Wu M; Yin Z
    Biochem Biophys Res Commun; 2012 Apr; 420(2):308-14. PubMed ID: 22425980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New serum biomarkers for detection of HBV-induced liver cirrhosis using SELDI protein chip technology.
    Zhu XD; Zhang WH; Li CL; Xu Y; Liang WJ; Tien P
    World J Gastroenterol; 2004 Aug; 10(16):2327-9. PubMed ID: 15285013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural history of chronic hepatitis B REVEALed.
    Chen CJ; Yang HI
    J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential proteomic biomarkers in assessing liver fibrosis using SELDI-TOF MS.
    Karatayli SC; Alagöz SG; Mizrak D; Sayki M; Ozkan M; Savaş B; Erden E; Cinar K; Idılman R; Yurdaydin C; Bozdayi AM
    Turk J Gastroenterol; 2012 Feb; 23(1):46-53. PubMed ID: 22505379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma.
    Schwegler EE; Cazares L; Steel LF; Adam BL; Johnson DA; Semmes OJ; Block TM; Marrero JA; Drake RR
    Hepatology; 2005 Mar; 41(3):634-42. PubMed ID: 15726646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of beta2-microgloblin as a candidate for early diagnosis of imaging-invisible hepatocellular carcinoma in patient with liver cirrhosis.
    Saito Y; Oba N; Nishinakagawa S; Mizuguchi Y; Kojima T; Nomura K; Nakatsura T
    Oncol Rep; 2010 May; 23(5):1325-30. PubMed ID: 20372847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The discrepancy of HBsAg titre and HBV DNA in patients with chronic hepatitis B, HBV-related liver cirrhosis and hepatocellular carcinoma].
    Pei YZ; Han T; Ma XY; Li Y; Xing J; Song ZL
    Zhonghua Gan Zang Bing Za Zhi; 2011 Oct; 19(10):743-6. PubMed ID: 22409845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of salivary N-glycome in HBV-induced chronic hepatitis, cirrhosis, and hepatocellular carcinoma.
    Qin Y; Zhong Y; Ma T; Zhang J; Yang G; Guan F; Li Z; Li B
    Glycoconj J; 2017 Aug; 34(4):523-535. PubMed ID: 28389847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement C4a inhibits the secretion of hepatitis B virus screened by surface-enhanced laser desorption ionization time-flight mass spectrometry-based ProteinChip analysis.
    Song YN; Zhang GB; Hu XQ; Lu YY; Zhao Y; Yang Y; Yang YF; Zhang YY; Hu YY; Su SB
    Proteomics Clin Appl; 2015 Dec; 9(11-12):1097-104. PubMed ID: 26119402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impacts of human leukocyte antigen DQ genetic polymorphisms and their interactions with hepatitis B virus mutations on the risks of viral persistence, liver cirrhosis, and hepatocellular carcinoma.
    Ji X; Zhang Q; Li B; Du Y; Yin J; Liu W; Zhang H; Cao G
    Infect Genet Evol; 2014 Dec; 28():201-9. PubMed ID: 25281206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.